Vericiguat
- Generic Name
- Vericiguat
- Brand Names
- Verquvo
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16F2N8O2
- CAS Number
- 1350653-20-1
- Unique Ingredient Identifier
- LV66ADM269
- Background
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst other cell t...
- Indication
适用于近期心力衰竭失代偿经静脉治疗后病情稳定的射血分数降低（射血分数<45%）的症状性慢性心力衰竭成人患者，以降低发生心力衰竭住院或需要急诊静脉利尿剂治疗的风险。
- Associated Conditions
- Cardiovascular Mortality, Heart Failure Hospitalization
- Associated Therapies
- -
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)
- Conditions
- Interventions
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 6105
- Registration Number
- NCT05093933
- Locations
- 🇨🇦
G A Research Associates ( Site 0652), Moncton, New Brunswick, Canada
🇺🇸South Florida Research Solutions ( Site 0058), Hollywood, Florida, United States
🇺🇸Georgia Arrhythmia Consultants and Research Institute ( Site 0042), Macon, Georgia, United States
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
- Conditions
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 5050
- Registration Number
- NCT02861534
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.